2. Natural Products
  3. Plants
  4. Araliaceae
  5. Panax ginseng C. A. Meyer

Panax ginseng C. A. Meyer

Synonyms: Ginseng

Panax ginseng C. A. Meyer (108):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0603
    20(S)-Ginsenoside Rg3 14197-60-5 99.82%
    20(S)-Ginsenoside Rg3 is the main component of Panax ginseng C. A. Meyer. Ginsenoside Rg3 inhibits Na+ and hKv1.4 channel with IC50s of 32.2±4.5 and 32.6±2.2 μM, respectively. 20(S)-Ginsenoside Rg3 also inhibits Aβ levels, NF-κB activity, and COX-2 expression.
    20(S)-Ginsenoside Rg3
  • HY-N0045
    Ginsenoside Rg1 22427-39-0 99.88%
    Ginsenoside Rg1 is one of the major active components of Panax ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.
    Ginsenoside Rg1
  • HY-N0039
    Ginsenoside Rb1 41753-43-9 99.75%
    Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits Na+, K+-ATPase activity with an IC50 of 6.3±1.0 μM. Ginsenoside also inhibits IRAK-1 activation and phosphorylation of NF-κB p65 .
    Ginsenoside Rb1
  • HY-N0605
    Ginsenoside Rh2 78214-33-2 99.28%
    Ginsenoside Rh2 (20(S)-Ginsenoside Rh2) induces the activation of caspase-8 and caspase-9. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner.
    Ginsenoside Rh2
  • HY-N0904
    Ginsenoside C-K 39262-14-1 99.93%
    Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.
    Ginsenoside C-K
  • HY-N19123
    Ginsenoside Ra9 1346522-92-6
    Ginsenoside Ra9 (Compound 6) is a protopanaxadiol-type ginsenoside. Ginsenoside Ra9 can be isolated from the roots of Panax ginseng.
    Ginsenoside Ra9
  • HY-N18026
    Ginsenoside V 1395101-76-4
    Ginsenoside V is a metabolite of Ginsenoside Rb1 (HY-N0039).
    Ginsenoside V
  • HY-N18029
    (24S)-Ginsenoside V 1679350-46-9
    (24S)-Ginsenoside V is a monooxygenated derivative of Ginsenoside Rb1 (HY-N0039). (24S)-Ginsenoside V is the major circulating metabolite of Ginsenoside Rb1 in rat plasma. (24S)-Ginsenoside V appears in rat urine after intravenous and oral administration of Ginsenoside Rb1 to rats.
    (24S)-Ginsenoside V
  • HY-N0040
    Ginsenoside Rb2 11021-13-9 99.87%
    Ginsenoside Rb2 is one of the main bioactive components of ginseng extracts. Rb2 can upregulate GPR120 gene expression. Ginsenoside Rb2 has antiviral effects.
    Ginsenoside Rb2
  • HY-N0044
    Ginsenoside Re 52286-59-6 99.92%
    Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.
    Ginsenoside Re
  • HY-N2515
    Ginsenoside Rk1 494753-69-4 99.90%
    Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB. Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis. Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway.
    Ginsenoside Rk1
  • HY-N0835
    (20S)-Protopanaxatriol 34080-08-5 99.93%
    (20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and estrogen receptor (ER), and is also a LXRα inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects.
    (20S)-Protopanaxatriol
  • HY-N1376
    (20R)-Ginsenoside Rg3 38243-03-7 99.84%
    (20R)-ginsenoside Rg3 ((20R)-Propanaxadiol), one of the active compounds present in ginseng root, inhibits angiogenesis, and has anti-carcinogenic and antimetastatic effects.
    (20R)-Ginsenoside Rg3
  • HY-N0797
    (20S)-Protopanaxadiol 30636-90-9 99.94%
    20S-protopanaxadiol (aPPD) is a metabolite of ginseng saponins, inhibits Akt activity and induces apoptosis in various tumor cells.
    (20S)-Protopanaxadiol
  • HY-N0604
    Ginsenoside Rh1 63223-86-9 98.72%
    Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β.
    Ginsenoside Rh1
  • HY-N0043
    Ginsenoside Rd 52705-93-8 99.88%
    Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.
    Ginsenoside Rd
  • HY-N0042
    Ginsenoside Rc 11021-14-0 98.0%
    Ginsenoside Rc, one of major Ginsenosides from Panax ginseng, enhances GABA receptorA (GABAA)-mediated ion channel currents (IGABA). Ginsenoside Rc inhibits the expression of TNF-α and IL-1β.
    Ginsenoside Rc
  • HY-N0601
    Ginsenoside Rf 52286-58-5 99.48%
    Ginsenoside Rf is a trace component of ginseng root. Ginsenoside Rf inhibits N-type Ca2+ channel.
    Ginsenoside Rf
  • HY-N0607
    Ginsenoside Ro 34367-04-9 99.81%
    Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155 μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.
    Ginsenoside Ro
  • HY-125848
    Ginsenoside F2 62025-49-4 99.92%
    Ginsenoside F2 is an orally active bioactive compound that participates in the regulation of metabolism and inflammation. Ginsenoside F2 promotes the phosphorylation of AMPK and ACC, binds to PPARγ, inhibits the phosphorylation of MAPK, activates the PI3K/AKT/GSK-3β pathway, reduces GLRX expression, and regulates lipid metabolism. Ginsenoside F2 reduces ROS production and MDA levels, restores SOD activity in cells, and alleviates oxidative stress. Ginsenoside F2 induces cell apoptosis (Apoptosis) and increases the number of cleaved caspase-3-positive cells. Ginsenoside F2 reduces body weight gain, adipose tissue weight and serum lipid levels in obese mice, and activates the hepatic AMPK signaling pathway and the expression of antioxidant enzymes. Ginsenoside F2 alleviates atopic dermatitis in mice by inhibiting inflammation and reshaping the gut microbiota. Ginsenoside F2 is applicable to research related to insulin resistance, obesity, atopic dermatitis, liver cancer, glioblastoma and glioma.
    Ginsenoside F2